CEA-Leti and Capsum announced that the successful transfer of Leti’s patented Lipidots nanovector technology to Capsum for cosmetic applications has produced the first commercial use of the new technology.
Lipidots is a nano-delivery platform based on tiny droplets of oil for encapsulating and carrying drugs or fluorescent imaging agents to targeted cells in the body for treatment or diagnosis. Leti’s partnership with Capsum shows that the technology is adaptable to applications in the cosmetics industry.
Capsum tailored the Lipidots technology for its NeoGoutttes, nano-emulsions that are used as a component in finished products and provide an efficient way of vectorising lipophilic or hydrophilic concentrates of active ingredients. The nanovector encapsulation protects active ingredients so they are conveyed through the skin for optimal effect.
This successful technology transfer follows more than seven years of collaboration between Leti and Capsum that included development work on Lipidots and it is the second recent announcement about Lipidots. In July, Leti announced €1 million (EUR) in funding from Banque Publique d’Investissement (BPIFrance) to accelerate the preclinical development of a liver-cancer detection system called LipImage 815.
Back to News
